ResearcherFirst Hospital of China Medical UniversityNo recent work listed

Simeng Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8271-2639; OpenAlex author ID A5102952359. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper

Papers 1

TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine. Co-author DOI 10.1007/s13167-022-00287-0 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qiaoyun Chu · 1 shared paper, 2022 · strength 0.19
- Paper TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, prev… DOI 10.1007/s13167-022-00287-0 ↗
Ce Li · 1 shared paper, 2022 · strength 0.19
- Paper TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, prev… DOI 10.1007/s13167-022-00287-0 ↗
Guan Wang · 1 shared paper, 2022 · strength 0.19
- Paper TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, prev… DOI 10.1007/s13167-022-00287-0 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.